BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30712845)

  • 21. Altered DNA Methylation Profiles in
    Pacholewska A; Grimm C; Herling CD; Lienhard M; Königs A; Timmermann B; Altmüller J; Mücke O; Reinhardt HC; Plass C; Herwig R; Hallek M; Schweiger MR
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
    Patton JT; Woyach JA
    Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Bruton's Tyrosine Kinase in CLL.
    Ahn IE; Brown JR
    Front Immunol; 2021; 12():687458. PubMed ID: 34248972
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH; Niesen E; Hallek M
    Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
    Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
    Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
    [No Abstract]   [Full Text] [Related]  

  • 29. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
    Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
    Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
    Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
    Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
    Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular bases of chronic lymphocytic leukemia in light of new treatments.
    Rossi D; Ciardullo C; Spina V; Gaidano G
    Immunol Lett; 2013; 155(1-2):51-5. PubMed ID: 24103588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.
    Mitsui T; Koiso H; Nakahashi H; Saitoh A; Shimizu H; Ishizaki T; Ogawa Y; Takizawa M; Yokohama A; Saitoh T; Jinbo T; Ogura H; Handa H; Sawamura M; Sakura T; Karasawa M; Murakami H; Nojima Y; Tsukamoto N
    Int J Hematol; 2016 Feb; 103(2):219-26. PubMed ID: 26588928
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Pozzo F; Bittolo T; Tissino E; Vit F; Vendramini E; Laurenti L; D'Arena G; Olivieri J; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Zucchetto A; Bomben R; Rossi FM; Del Poeta G; Dal Bo M; Gattei V
    Haematologica; 2021 Dec; 106(12):3125-3135. PubMed ID: 33121237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
    J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
    Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.